Protalix Biotherapeuticss
Monday, February 26, 2024
Plymouth
Gene/Cell Therapy
Protalix is a commercial-stage biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx, and expertise in protein modification chemistries.
It was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix’s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
State
Israel
Country
Israel
Website
http://www.protalix.com
CEO/Top Company Official
Dror Bashan
Lead Product in Development
PRX-115, PRX-119
Development Phase of Primary Product
Multiple Products in Market
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}